OZEM

Roundhill GLP-1 & Weight Loss ETF
OZEM

$28.47

0.7%

Market Cap: $47M

0

Funds holding %

of 6,728 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

90% more call options, than puts

Call options by funds: $173K | Put options by funds: $91K

15.12% more ownership

Funds ownership: 0% [Q1] → 15.12% (+15.12%) [Q2]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for OZEM.

See Analyst Rankings

Financial journalist opinion

Zacks Investment Research

Tap the Weight-Loss Drug Market With These ETFs

Investors seeking to tap the boom in weight-loss drug treatment could consider these ETFs.

Tap the Weight-Loss Drug Market With These ETFs

CNBC Television

Mag7, AI and GLP-1: Roundhill CEO on the hottest ETFs to watch

Dave Mazza, Roundhill Investments CEO, joins CNBC's Bob Pisani on “Halftime Report's” “ETF Edge” segment to discuss the firms' three ETFs following the Mag7, AI and GLP-1 themes.

Mag7, AI and GLP-1: Roundhill CEO on the hottest ETFs to watch

Disruptive Theme of the Week: Playing Defense

When markets correct, it is a good time to revisit which equity market sectors are “defensive” themes. Certain products and services are nondiscretionary in nature that we cannot live without.

Disruptive Theme of the Week: Playing Defense

Zacks Investment Research

ETFs in Focus as Competition Heats Up in Weight Loss Drug Segment

Two companies, Eli Lilly (LLY) and Novo Nordisk (NVO), have so far dominated the weight-loss drug market. Now, Roche recently announced encouraging Phase I trial data for its new obesity drug candidate.

ETFs in Focus as Competition Heats Up in Weight Loss Drug Segment

Top Themes in the First Half of 2024: Crypto, Chips, Ships & Silver

After a torrid risk-on run in the first quarter of 2024, markets cooled off a bit but ended the half still positive with mid-double-digit returns. Technology themes such as cryptocurrency and artificial intelligence helped propel markets higher.

Top Themes in the First Half of 2024: Crypto, Chips, Ships & Silver

Why Investors Haven't Feasted on Two New Weight-Loss ETFs

Two new weight-loss exchange-traded funds (ETFs) launched in May have yet to whet investors' appetite, possibly due to their expensive fees and concentrated bets.

Why Investors Haven't Feasted on Two New Weight-Loss ETFs

OZEM: Investing in the Weight Loss Craze

Roundhill Investments launched its GLP-1 and Weight Loss ETF (OZEM) on May 21st. Dave Mazza discusses investing in the weight loss craze.

OZEM: Investing in the Weight Loss Craze

OZEM ETF: 7 Things to Know About the New Roundhill GLP-1 & Weight Loss ETF

As weight loss drugs are gaining popularity a new way to invest in the companies behind these products has launched with the Roundhill GLP 1 And Weight Loss ETF (NASDAQ:OZEM). Let's get into everything investors need to know about this new weight loss exchange-traded fund (ETF) before investing in OZEM stock below!

OZEM ETF: 7 Things to Know About the New Roundhill GLP-1 & Weight Loss ETF

This new weight loss drug ETF bets big on two of the industry's leading players

While Novo Nordisk and Eli Lilly have soared in the past year, Roundhill Investments sees bigger gains ahead for the GLP-1 drugmakers.

This new weight loss drug ETF bets big on two of the industry's leading players

This Week in ETFs: Roster of 17 New ETFs Includes 6 Buffer Funds

The week ended May 24, 2024 saw the rollout of 17 new ETFs, including six defined outcome funds. The total count was the highest it's been in several weeks, with launches slowing notably in the weeks around the Easter and Passover holidays.

This Week in ETFs: Roster of 17 New ETFs Includes 6 Buffer Funds

See News Rankings